Step 1 topics → Reproductive → Breast Carcinoma (DCIS, IDC, ILC, Paget, Inflammatory)

Breast Carcinoma (DCIS, IDC, ILC, Paget, Inflammatory)

USMLE Step 1 trap: Treats LCIS like DCIS requiring surgical excision with clear margins. LCIS is a risk marker for future bilateral breast cancer, not a direct precursor, and does not require margin-free excision.

Breast carcinoma is one of the highest-yield pathology topics on USMLE Step 1, and the exam hits it from multiple angles: histologic identification, clinical presentation, receptor-based management, and genetic risk. You need to know not just what each subtype looks like, but what distinguishes it from the others — because the exam loves to pit DCIS against LCIS, or invasive ductal against invasive lobular, in ways that punish students who learned surface-level facts without understanding the underlying biology.

The trickiest part of this topic is that the names are misleading. 'Inflammatory' breast cancer isn't inflammatory. 'Lobular carcinoma in situ' isn't really a precursor that needs to be cut out. Paget disease of the breast isn't a skin disease. USMLE Step 1 exploits exactly these naming traps — a vignette will describe classic findings and ask you to pick the next step, the mechanism, or the prognosis, and the right answer depends on understanding what's actually happening biologically, not just pattern-matching the name.

Receptor subtype management (ER/PR → tamoxifen or aromatase inhibitors; HER2 → trastuzumab; triple-negative → chemotherapy only) is tested both in isolation and in application. BRCA1/2 comes up in risk-reduction counseling and in explaining why a young woman with bilateral, triple-negative cancer is high-risk. These aren't just memorization items — Step 1 wants you to apply them to novel clinical scenarios.

From real student decks
78%have cards covering this topic
62%have mature cards
1median lapses in 14 days

Common misconceptions

Common mistake
Wrong: LCIS is a direct precursor lesion that must be excised to clear margins.
Right: LCIS is a risk marker for future bilateral breast cancer, not a direct precursor, and does not require margin-free excision.
LCIS is not a direct precursor lesion the way DCIS is — it doesn't progress in a linear fashion to invasive lobular carcinoma at that site. Instead, it signals a field defect: the entire breast tissue (bilaterally) has elevated risk for future invasive cancer. This is why margin status is irrelevant for LCIS — you're not trying to excise a lesion that will become cancer there; you're identifying a patient who needs increased surveillance of both breasts.
Common mistake
Wrong: Invasive lobular carcinoma forms a palpable mass like invasive ductal carcinoma.
Right: Invasive lobular carcinoma grows in single-file lines (Indian-file pattern) and often lacks a discrete mass, making it harder to detect clinically and mammographically.
Invasive lobular carcinoma cells lose E-cadherin (a cell adhesion molecule), which is why they don't stick together to form a cohesive mass. Instead they infiltrate stroma in single-file lines, diffusely and insidiously. This makes ILC notoriously hard to feel on exam and easy to miss on mammography — a patient with ILC may have significant tumor burden without a palpable lump, which is the opposite of what you'd expect from invasive ductal carcinoma.
Common mistake
Wrong: Paget disease of the breast is a primary skin condition limited to the nipple epidermis.
Right: Paget disease of the breast represents intraepidermal spread of an underlying ductal carcinoma and requires workup for underlying malignancy.
The eczematous, crusting nipple changes in Paget disease look dermatologic, but the Paget cells (large cells with clear halos in the nipple epidermis) are actually malignant ductal cells that have migrated up from an underlying ductal carcinoma — either DCIS or invasive. Treating it as dermatitis and prescribing topical steroids is a dangerous error. The correct next step is imaging and biopsy to identify the underlying breast malignancy.
Common mistake
Wrong: Inflammatory breast cancer causes redness and warmth because it triggers an immune inflammatory response.
Right: Inflammatory breast cancer causes peau d'orange skin changes because tumor emboli obstruct dermal lymphatics, not due to true inflammation.
The name 'inflammatory breast cancer' refers to its appearance, not its etiology. There is no significant immune infiltrate causing the redness and warmth — instead, tumor emboli block dermal lymphatic channels, causing lymphedema of the overlying skin. This lymphedema tethers the skin at hair follicle openings, producing the classic peau d'orange ('orange peel') texture. It is aggressive precisely because it spreads via lymphatics early and extensively.
Common mistake
Wrong: Triple-negative breast cancer can be treated with trastuzumab or tamoxifen.
Right: Triple-negative breast cancer lacks ER, PR, and HER2 expression, making it ineligible for hormonal or HER2-targeted therapy and reliant on chemotherapy.
Triple-negative breast cancer (TNBC) is defined by the absence of estrogen receptor, progesterone receptor, and HER2 overexpression — meaning it has none of the molecular handles that targeted therapies grab onto. Tamoxifen blocks ER (no ER here), aromatase inhibitors reduce estrogen (irrelevant without ER), and trastuzumab targets HER2 (not expressed). TNBC is treated with conventional chemotherapy, carries a worse prognosis, and is disproportionately associated with BRCA1 mutations.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Distinguish DCIS from LCIS: understand that DCIS is a true precursor requiring clear surgical margins, while LCIS is a bilateral risk marker that does not require margin-negative excision.
  2. Identify invasive ductal carcinoma versus invasive lobular carcinoma by histologic pattern — ductal forms a discrete mass with gland-like structures, while lobular grows in single-file Indian-file lines and often lacks a palpable mass.
  3. Recognize Paget disease of the breast from its clinical description (eczematous nipple changes) and know that it signals an underlying ductal carcinoma that must be worked up, not treated as a primary skin condition.
  4. Explain the mechanism behind inflammatory breast cancer's skin findings — dermal lymphatic obstruction by tumor emboli causes peau d'orange, not true immune-mediated inflammation.
  5. Apply receptor subtype to management: ER/PR-positive tumors respond to hormonal therapy, HER2-positive to trastuzumab, and triple-negative breast cancer has no targeted therapy and requires cytotoxic chemotherapy.
  6. Know the cancer risks associated with BRCA1 and BRCA2 mutations (breast, ovarian, and others) and the risk-reducing interventions (prophylactic mastectomy, oophorectomy, enhanced surveillance).

Can you avoid these mistakes?

A 45-year-old woman has a core needle biopsy showing lobular carcinoma in situ with positive margins. What is the appropriate next management step, and why does margin status matter differently here than it would for DCIS?
A 60-year-old woman presents with a thickened, erythematous breast and skin that has the texture of an orange peel. She has no fever and her CBC is normal. What is the mechanism behind her skin findings, and what does the absence of fever tell you about this diagnosis?
A pathology report describes a breast tumor with cells growing in single-file lines through the stroma without forming glands or a discrete mass. What is this tumor, what molecular change explains this growth pattern, and how does this affect clinical detection?
A 38-year-old woman with a BRCA1 mutation is diagnosed with a breast tumor that is ER-negative, PR-negative, and HER2-negative. What treatment category applies, and why is BRCA1 mutation specifically associated with this receptor subtype?

Related topics

Breast Anatomy and Lymphatic Drainage Gonadal Differentiation (SRY, MIS, Testosterone) Müllerian vs Wolffian Duct Derivatives 5α-Reductase Deficiency Complete Androgen Insensitivity Syndrome (CAIS)

See how your Anki deck covers this topic.

Upload your deck for a free audit →